NCT00234702 - Efficacy and Safety of Lanthanum Carbonate in Reducing Serum Phosphorus Levels in Subjects With Stage 3 and 4 Chronic Kidney Disease | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 11, 2006

Primary Completion Date

June 1, 2007

Study Completion Date

June 1, 2007

Conditions

Kidney Diseases

Interventions

DRUG

Lanthanum carbonate

Lanthanum carbonate 750mg/day, T.I.D. for 2 weeks; titrated at the next 3 weekly visits in order to achieve target serum phosphorus levels, up to a maximum dose of 3000mg/day; 4-week maintenance period where subject receives the final titrated daily dose established during the titration period.

DRUG

Placebo

Trial Locations (10)

27599

University of North Carolina, Chapel Hill

34667

Outcomes Research International, Inc., Hudson

55430

Twin Cities Clinical Research, Brooklyn Center

63110

St. Louis University/Nephrology, St Louis

77030

Kidney Associates, Houston

80260

Western Nephrology & Metabolic Bone Disease, PC, Thornton

90073

VA Greater Los Angeles Health Care System, Los Angeles

90503

Barnett Research & Communications Medical Corporation, Torrance

97210

Northwest Renal Clinic, Portland

Unknown

Nephrology Associates, Nashville